Clinical Trial for Hepatic Encephalopathy and Liver Cirrhosis

Liver cirrhosis is a chronic condition where healthy liver tissue is replaced with scar tissue, limiting the liver’s ability to function properly. Over time, cirrhosis can lead to serious complications, including hepatic encephalopathy (HE)—a condition marked by confusion, forgetfulness, and even coma due to the buildup of toxins in the brain that the damaged liver can no longer filter effectively. These symptoms can severely affect a patient’s quality of life and may worsen without timely intervention.

Lucida Clinical Trials is conducting a Phase 3 clinical trial designed to evaluate an investigational treatment for individuals living with liver cirrhosis. This study is focused on patients who have medically controlled ascites—a common complication of cirrhosis—and aims to determine whether the investigational drug can delay the first serious episode of overt hepatic encephalopathy (OHE), a condition that can cause confusion, personality changes, and other cognitive issues.